Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?

References

• Shore ND, Palou Redorta J, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021;39(10):642–663. doi: 10.1016/j.urolonc.2021.05.015
   PubMed Web of Science ®Google Scholar
• Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015;31(4):297–303. doi: 10.4103/0970-1591.166446
   PubMedGoogle Scholar
• Chehroudi AC, Black PC. Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: charting a path forward. Can Urol Assoc J. 2020 Jun;14(6):204–213. doi: 10.5489/cuaj.6101
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi: 10.1016/j.eururo.2019.08.016
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029. doi: 10.1016/j.juro.2016.06.049
   PubMed Web of Science ®Google Scholar
• Tully KH, Roghmann F, Noldus J, et al. Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed T1 non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2020 Dec;18(6):e651–e659.
   PubMed Web of Science ®Google Scholar
• Collacott H, Krucien N, Heidenreich S, et al. Patient preferences for treatment of bacillus calmette-guérin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment. Eur Urol Open Sci. 2023;49:92–99. doi: 10.1016/j.euros.2022.12.016
   PubMedGoogle Scholar
• Harvey M, Chislett B, Perera M, et al. Critical shortage in BCG immunotherapy: how did we get here and where will it take us? Urol Oncol. 2022;40(1):1–3. doi: 10.1016/j.urolonc.2021.09.022
   PubMed Web of Science ®Google Scholar
• Tan WS, Kelly JD. Is delay to radical cystectomy following BCG failure oncologically safe? Nat Rev Urol. 2021;18(6):323–324. doi: 10.1038/s41585-021-00457-1
   PubMed Web of Science ®Google Scholar
• Abou Chakra M, Packiam VT, O’Donnell MA. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer [published online ahead of print, 2023 Oct 16]. Expert Opin Pharmacother. 2023;24(18):1–11. doi: 10.1080/14656566.2023.2271396
   PubMed Web of Science ®Google Scholar
• Nazmifar M, Williams C, Naser-Tavakolian A, et al. Clinical and preclinical therapies for bladder cancer following bacillus Calmette-Guérin failure. J Urol. 2023;209(1):32–48. doi: 10.1097/JU.0000000000002957
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Breyer BN, Whitson JM, Carroll PR, et al. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28(5):510–514. doi: 10.1016/j.urolonc.2008.11.019
   PubMed Web of Science ®Google Scholar
• Chevuru PT, McElree IM, Mott SL, et al. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol. 2023;41(3):148.e1–148.e7. doi: 10.1016/j.urolonc.2022.10.030
   PubMed Web of Science ®Google Scholar
• Cockerill PA, Knoedler JJ, Frank I, et al. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int. 2016;117(3):456–462. doi: 10.1111/bju.13088
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and Docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902–909. doi: 10.1097/JU.0000000000000688
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, O’Donnell MA, et al. Sequential intravesical gemcitabine and Docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1(1):65–72. doi: 10.3233/BLC-150008
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Packiam VT, Thomas LJ, et al. Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol. 2022;40(1):9.e1–9.e7. doi: 10.1016/j.urolonc.2021.03.024
   PubMed Web of Science ®Google Scholar
• Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293–303. doi: 10.3233/BLC-170126
   PubMed Web of Science ®Google Scholar
• Lightfoot AJ, Breyer BN, Rosevear HM, et al. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol Oncol. 2014;32(1):.e35.15–.e35.19. doi: 10.1016/j.urolonc.2013.01.009
   Web of Science ®Google Scholar
• McElree IM, Steinberg RL, Martin AC, et al. Sequential intravesical gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve high-risk nonmuscle-invasive bladder cancer. J Urol. 2022;208(3):589–599. doi: 10.1097/JU.0000000000002740
   PubMed Web of Science ®Google Scholar
• McElree IM, Steinberg RL, Mott SL, et al. Comparison of sequential intravesical gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw Open. 2023;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849
   PubMed Web of Science ®Google Scholar
• Babajide R, Labbate C, Saoud R, et al. Early experience with intravesical gemcitabine-docetaxel for BCG-Naïve patients with high grade non-muscle invasive bladder cancer. Urol Oncol. 2020;38(12):901. doi: 10.1016/j.urolonc.2020.10.038
   Web of Science ®Google Scholar
• Pareek T, Parmar K, Sharma AP, et al. Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a Pilot study. Urol Int. 2022;106(8):784–790. doi: 10.1159/000524098
   PubMed Web of Science ®Google Scholar
• Yim K, Melnick K, Mott SL, et al. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy [published online ahead of print, 2023 Sep 8]. Urol Oncol. 2023;S1078-1439(23):00229–6.
   Google Scholar
• Tan WS, McElree IM, Davaro F, et al. Sequential intravesical gemcitabine and Docetaxel is an alternative to Bacillus Calmette-Guérin for the treatment of intermediate-risk non-muscle-invasive bladder cancer [published online ahead of print, 2023 Jul 18]. Eur Urol Oncol. 2023;S2588-9311(23):00143–8.
   Google Scholar
• McElree IM, Orzel J, Stubbee R, et al. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer [published online ahead of print, 2023 Jul 11]. Urol Oncol. 2023;S1078-1439(23):00228–4.
   Google Scholar
• Musat MG, Kwon CS, Masters E, et al. Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR). Clinicoecon Outcomes Res. 2022 Jan 10;14:35–48.
   PubMed Web of Science ®Google Scholar
• Steinberg RL, O’Donnell MA, Packiam VT. Nonrisk-adapted sequential intravesical gemcitabine and docetaxel for Nonmuscle-invasive bladder cancer: the time is Now. J Urol. 2023;210(1):5–7. doi: 10.1097/JU.0000000000003438
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lerner SP, Kluetz PG, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American Urological Association public workshop. Urology. 2014;83(2):262–264. doi: 10.1016/j.urology.2013.10.030
   PubMed Web of Science ®Google Scholar
• Kawada T, Yanagisawa T, Araki M, et al. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Curr Opin Urol. 2023;33(3):211–218. doi: 10.1097/MOU.0000000000001065
   PubMed Web of Science ®Google Scholar
• Kohada Y, Hayashi T, Hsi RS, et al. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. BJU Int. 2021;127(4):473–485. doi: 10.1111/bju.15209
   PubMed Web of Science ®Google Scholar
• Barlow LJ. Non-muscle-invasive bladder cancer management during BCG shortages: NYU case of the Month, February 2020. Rev Urol. 2020;22(1):35–36.
   PubMedGoogle Scholar
• Li R, Sundi D, Zhang J, et al. Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical bacillus Calmette-Guérin. Eur Urol. 2020;78(3):387–399. doi: 10.1016/j.eururo.2020.02.012
   PubMed Web of Science ®Google Scholar
• Bukavina L, Bell S, Packiam VT, et al. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: a preliminary cost-effectiveness analysis. Urol Oncol. 2023;41(9):391.e1–391.e4. doi: 10.1016/j.urolonc.2023.04.005
   PubMed Web of Science ®Google Scholar
• Koch GE, Smelser WW, Chang SS. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021;149:11–20. doi: 10.1016/j.urology.2020.10.039
   PubMed Web of Science ®Google Scholar